================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 4, 2005
Date of Report
(Date of earliest event reported)
ADVANCIS PHARMACEUTICAL CORPORATION
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-50414 52-2208264
---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
20425 Seneca Meadows Parkway, Germantown, Maryland 20876
-------------------------------------------------- ----------
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (301) 944-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13a-4(c))
================================================================================
ITEM 2.02. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On August 4, 2005, Advancis Pharmaceutical Corporation issued a press
release announcing its financial results for the three months ended June 30,
2005. A copy of the release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto shall
not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, except as shall be expressly set forth by
specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit Description
------- -------------------------------------------------------------
99.1 Press Release issued August 4, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ADVANCIS PHARMACEUTICAL CORPORATION
Date: August 4, 2005 By: /s/ Steven A. Shallcross
------------------------------
Steven A. Shallcross
Senior Vice President and
Chief Financial Officer